The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Zavadenko N.N.

Pirogov Russian National Research Medical University

Zykov V.P.

Gaynetdinova D.D.

Agranovich O.V.

Chutko L.S.

Kovalev G.I.

Nemkova S.A.

Rogatkin S.O.

Chekalova S.A.

Panova L.D.

Sarvilina I.V.

Nesterovsky Y.E.

Ganina N.V.

Yurlova O.V.

Multidisciplinary consensus on the use of Cereton drug in treatment of central nervous system diseases with cognitive impairments of congenital and acquired origin in children. Resolution of the multidisciplinary panel of experts

Authors:

Zavadenko N.N., Zykov V.P., Gaynetdinova D.D., Agranovich O.V., Chutko L.S., Kovalev G.I., Nemkova S.A., Rogatkin S.O., Chekalova S.A., Panova L.D., Sarvilina I.V., Nesterovsky Y.E., Ganina N.V., Yurlova O.V.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2024;124(7): 145‑153

DOI: 10.17116/jnevro2024124071145

Read: 993 times

Download PDF (RU)
Contact the author
Table of contents

MULTIDISCIPLINARY CONSENSUS ON THE USE OF CERETON DRUG IN TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES WITH COGNITIVE IMPAIRMENTS OF CONGENITAL AND ACQUIRED ORIGIN IN CHILDREN. RESOLUTION OF THE MULTIDISCIPLINARY PANEL OF EXPERTS
MULTIDISCIPLINARY CONSENSUS ON THE USE OF CERETON DRUG IN TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES WITH COGNITIVE IMPAIRMENTS OF CONGENITAL AND ACQUIRED ORIGIN IN CHILDREN. RESOLUTION OF THE MULTIDISCIPLINARY PANEL OF EXPERTS

To cite this article:

Zavadenko NN, Zykov VP, Gaynetdinova DD, et al. . Multidisciplinary consensus on the use of Cereton drug in treatment of central nervous system diseases with cognitive impairments of congenital and acquired origin in children. Resolution of the multidisciplinary panel of experts. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;124(7):145‑153. (In Russ.)
https://doi.org/10.17116/jnevro2024124071145

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
 
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Abstract:

On February 27, 2024, in Moscow, on the threshold of the congress with international participation “Movement Disorders in Children”, an interdisciplinary council of experts was held to determine an optimized algorithm for the management of pediatric patients with diseases of the nervous system of congenital and acquired genesis with clinical manifestations of neuropsychiatric developmental disorders and cognitive disorders. The Council of Experts developed recommendations on the use of Cereton (CJSC Pharm-Firm Sotex, Russia) – the only choline alphoscerate approved in pediatrics - in the therapy of cognitive disorders in children, as well as management regimens for such patients using both capsule and liquid oral forms of the drug.

The resolution noted the prospect of effective use of the drug Cereton for the correction of neuropsychiatric development disorders and restoration of cognitive functions in children, as well as the need to consider and include this drug in clinical recommendations and standards of medical care in neuropediatrics.

Authors:

Zavadenko N.N.

Pirogov Russian National Research Medical University

Zykov V.P.

Gaynetdinova D.D.

Agranovich O.V.

Chutko L.S.

Kovalev G.I.

Nemkova S.A.

Rogatkin S.O.

Chekalova S.A.

Panova L.D.

Sarvilina I.V.

Nesterovsky Y.E.

Ganina N.V.

Yurlova O.V.

Received:

22.06.2024

Accepted:

26.06.2024

Close metadata

References:

  1. Zdravookhranenie v Rossii. 2021. Statisticheskij sbornik. Rosstat. M. 2021. (In Russ.).
  2. Baranov AA, Albitsky VYu, Modestov AA, et al. Morbidity of the Russian child population (results of a comprehensive medical and statistical study). Zdravookhranenie Rossijskoj Federatsii. 2012;5:21-26. (In Russ.).
  3. Zavadenko NN, Nemkova SA. Narusheniya razvitiya i kognitivnye disfunktsii u detej s zabolevaniyami nervnoj sistemy. M.: MEDpress-inform; 2016. (In Russ.).
  4. Karkashadze GA, Maslova OI, Namazova-Baranova LS. Current problems of diagnosis and treatment of mild cognitive impairments in children. Pediatricheskaya farmakologiya. 2011;8(5):37-41. (In Russ.).
  5. Nemkova SA. Kognitivnye narusheniya pri detskom tserebral’nom paraliche. M.: Triada-Kh; 2013. (In Russ.).
  6. Gainetdinova DD, Semenov VV, Ismagilov MF, et al. Clastogenic, aneugenic, prooxidant and antioxidant properties of some neurotropic drugs. Eksperimental’naya i klinicheskaya farmakologiya. 2006;69(3):58-62. (In Russ.). https://doi.org/10.30906/0869-2092-2006-69-3-58-62
  7. Maslova OI, Baranov AA, Namazova-Baranova LS, et al. Modern aspects of studying the cognitive sphere in child development. Pediatricheskaya farmakologiya. 2012;9(6):72-78. (In Russ.). https://doi.org/10.15690/pf.v9i6.521
  8. Detskaya nevrologiya. Klinicheskie rekomendatsii. Guzeva VI, ed. M.: IMK; 2015. (In Russ.).
  9. Federal’noe rukovodstvo po detskoj nevrologii. Guzeva VI, ed. 2023. (In Russ.).
  10. Chutko LS, Yakovenko EA, Surushkina SYu, et al. Clinical and neurophysiological heterogeneity of attention deficit hyperactivity disorder. S.S. Korsakov Journal of Neurology and Psychiatry. 2016,10:117-121. (In Russ.). https://doi.org/10.17116/jnevro2016116101117-121
  11. Chutko LS, Surushkina SYu, Nikishena IS, et al. Treatment of attention deficit syndrome with comorbid tic hyperkinesis. S.S. Korsakov Journal of Neurology and Psychiatry. 2008;2:45-48. (In Russ.).
  12. Zykov VP. Ischemic stroke in children. M.: MAI-Print; 2011. (In Russ.).
  13. Chekalova SA, Vorobyeva VA, Bogomolova ES, et al. Modern view on the problem of school adaptation. Remedium Privolzh’e. 2014;5(125):24-27. (In Russ.).
  14. Nemkova SA. Modern principles of integrated diagnostics and rehabilitation of perinatal lesions of the nervous system and their consequences. S.S. Korsakov Journal of Neurology and Psychiatry. 2017;117(3):40-49. (In Russ.). https://doi.org/10.17116/jnevro20171173140-49.
  15. Zavadenko N, Nesterovskiy Y, Kholin A, et al. Neurobehavioral, Cognitive, and Paroxysmal Disorders in the Long-Term Period of Pediatric Traumatic Brain Injury. Advancement and New Understanding in Brain Injury. IntechOpen; 2021, Chapter 11. 
  16. Nemkova SA. Modern principles of integrated diagnostics and rehabilitation of perinatal lesions of the nervous system and their consequences. S.S. Korsakov Journal of Neurology and Psychiatry. 2017;117(3):40-49. (In Russ.). https://doi.org/10.17116/jnevro20171173140-49
  17. Hishida M, Anjum R, Anada T, et al. Effect of Osmolytes on Water Mobility Correlates with Their Stabilizing Effect on Proteins. J Phys Chem B. 2022;126(13):2466-2475. https://doi.org/10.1021/acs.jpcb.1c10634
  18. Liquid syrup preparation containing choline alfoscerate, 2018. WO2019208898A1.
  19. Ae-Gyeoing Im, Go-Wun Choi, Dong Wook Kang, et al. Population pharmacokinetic modeling and simulation of choline in healthy Korean subjects after oral administration of choline alfoscerate. Journal of Pharmaceutical Investigation. 2022;52:331-339.  https://doi.org/10.1007/s40005-022-00562-2
  20. Lee S, Choi B, Kim J, et al. Late treatment with choline alfoscerate (l-alpha glycerylphosphorylcholine, α-GPC) increases hippocampal neurogenesis and provides protection against seizure-induced neuronal death and cognitive impairment. Brain Res. 2017;1654(Pt A):66-76.  https://doi.org/10.1016/j.brainres.2016.10.011
  21. Starchina YuA. The use of the drug cereton in neurological practice. Nevrologiya, nejropsikhiatriya, psikhosomatika. 2011;3(2):81-84. (In Russ.).
  22. Shishkova VN. Modern possibilities of neurorehabilitation: prospects of drug support in different periods of recovery. Nervnye bolezni. 2020;2:75-77. (In Russ.).
  23. Stulin ID, Musin RS, Solonsky DS. The effectiveness of choline alfoscerate (Cereton) in patients with chronic cerebral ischemia. S.S. Korsakov Journal of Neurology and Psychiatry. 2009;7:87-89. (In Russ.).
  24. Mendelevich EG, Surzhenko IL, Dunin DN, et al. Tsereton in the treatment of cognitive impairment in patients with dyscirculatory and post-traumatic encephalopathy. Russkij meditsinskij zhurnal. 2009;17(5):384-386. (In Russ.).
  25. Kamchatnov PR, Abusueva BA, Evzelman MA, et al. The effectiveness of cereton in acute ischemic stroke (results of the SUN study). S.S. Korsakov Journal of Neurology and Psychiatry. 2012;112(3-2):10-14. (In Russ.).
  26. Maslova NN, Pysina AM. Multiple sclerosis: the state of the problem. Meditsinskie vesti regionov. 2009;1:23-27. (In Russ.).
  27. Zafonte R, Friedewald W, Lee S, et al. The Citicoline Brain Injury Treatment (COBRIT) Trial: Design and Methods. J Neurotrauma. 2009;2(12):2207-2216.
  28. Federal clinical guidelines for the provision of medical care to children with the consequences of perinatal damage to the central nervous system with diffuse muscular hypotension. M.: Soyuz pediatrov Rossii; 2013. (In Russ.).
  29. Thomas J, Warren K, Hewitt B. Fetal alcohol spectrum disorders: from research to policy. Alcohol Res Health. 2010;33(1-2):118-126. 
  30. Litvin LB. The use of Gliaton in the treatment of disorders of psychological development in children. Mezhdunarodnyj nevrologicheskij zhurnal. 2014;N5(67):159-162. (In Russ.).
  31. Krasnoperova MG, Bashina VM. Gliatilin in childhood autism treatment. 9th International Multidisciplinary Conference of Biological Psychiatry “Stress and Behavior”. Proceedings of the 9th International Multidisciplinary Conference “Stress and behavior”. Saint Petersburg, Russia, May 16-19, 2005.
  32. Fesenko YuV, Fesenko YuA. Psychopharmacotherapy in the complex treatment of children with attention deficit hyperactivity disorder. Prakticheskaya meditsina. 2009;6(38):71-76. (In Russ.).
  33. Gainetdinova DD, Agranovich OV, Nemkova SA, et al. The results of a multicenter, double-blind, randomized, placebo-controlled clinical trial to evaluate the efficacy, safety and tolerability of the drug Cereton in the treatment of cognitive impairment in children in the recovery period of traumatic brain injury and hemorrhagic stroke. Effektivnaya farmakoterapiya. Nevrologiya i psikhiatriya. 2024;20(14):6-14. (In Russ.). https://doi.org/10.33978/2307-3586-2024-20-14-6-14
  34. Rafikova ZB, Nurmatova DA, Tashbekova DB. The effectiveness of outpatient comprehensive treatment of adolescents with learning difficulties and school adaptation using the drug Cereton. RMZh. 2015;16:938. (In Russ.).
  35. Potupchik TV, Veselova OF, Evert LS, et al. Correction of cognitive impairment in children using nootropic drugs. Obozrenie psikhiatrii i meditsinskoj psikhologii imeni V.M. Bekhtereva. 2015;3:109-113. (In Russ.).
  36. Potupchik TV, Evert LS, Burlakova AV. The possibilities of using nootropic drugs for cognitive impairment in children in the postcovid period. Meditsinskaya sestra. 2022;24(4):3-7. (In Russ.). https://doi.org.10.29296/25879979-2022-04-01
  37. Nurmatova ShO, Sherova ZN, Turabekova ShKh. Inclusion of the drug Cereton in the complex therapy of patients with cerebral palsy. Mirovye nauchnye issledovaniya i razrabotki v epokhu tsifrovizatsii. Rostov-na-Donu. 2021:288-291. (In Russ.).
  38. Polushina NV. The use of the drug Cereton in the treatment of diseases of the nervous system in children and adolescents. Russkij meditsinskij zhurnal. 2009;17(11):770-773. (In Russ.).
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.